Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Clinical trial NCT02787005 · COMPLETED
Trial details
- NCT number
- NCT02787005
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2022-02-28
- Enrollment
- 388
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.